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secondary prevention strategies, and to develop effective therapeutic interventions for individuals who are
already symptomatic. One of the critically important pieces of all national plans to address AD is the call
for thedevelopment of servicemodels todeliver quality, effective carebasedon thebest evidenceavailable.
Methods: We describe one type of care model developed by the Fundacio ACE, Institut Catala de
Neurociencies Aplicades (Fundacio ACE, Barcelona, Spain) that integrates diagnosis, therapy,
follow-up care, daycare, and a day hospital, and does so in the context of an active clinical research
and educational program.
Results: There were 13,048 individuals newly evaluated and diagnosed in Fundacio ACE between 1996
and 2011. Of these, 6132 hadAD (47.0%), 3871 hadmild cognitive impairment (MCI) (29.7%), and 1958
had no cognitive impairment (15.0%). Follow-up information is available on 4735 (47.3%) AD andMCI
patients, and thesedata indicate thatMCIdevelops intodementia at a rate of 222.6/1000person-years.Apo-
lipoprotein E (APOE) genotypingwas available in 22.4%of the patients. The4 allele occurred in 45.7%of
the AD patients, in 37.8% of the MCI subjects, and in 31.6% of those without cognitive impairment.
Conclusions: Fundacio ACE can serve as a model system that can be adapted to other settings within
their specific cultural, governmental, and legal constraints.
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16/j.jalz.2013.03.006(AD) [1,2]. The number of cases, in both absolute and
relative terms, is expected to increase substantially as the
population continues to age, in some cases tripling during
the next 25 years [3]. As a consequence, there is an increas-
ing international effort to understand the biology of AD to
develop primary and secondary prevention strategies, as
well as to develop effective therapeutic interventions for
individuals who are already symptomatic. In response to
these needs, the U.S. government passed the National
Alzheimer’s Project Act on January 4, 2011 [4], which
required the secretary of the U.S. Department of Health
and Human Services to establish the National Alzheimer’s
Project to create and maintain an integrated national plan
to overcome AD; to coordinate AD research and serviceseserved.
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treatments that would prevent, halt, or reverse the course of
AD; to improve early diagnosis and coordination of care and
treatment of AD; to improve outcomes for ethnic and racial
minority populations that are at higher risk for AD; and to
coordinate with international bodies to fight AD globally.
At the same time as the National Alzheimer’s Project
was being developed, a special subcommittee on aging of
the U.S. Senate released its report comparing international
approaches to AD and dementia [3]. The subcommittee
reached several conclusions based on their analysis. First,
medical professionals “do not and cannot always properly
diagnose” AD (pg. 85). Second, there is an international
effort to develop home- and community-based services
within existing health care delivery systems so that individ-
uals with dementia can remain in their own home for as
long as possible. Third, as a consequence of this desire to
preserve autonomy in individuals with dementia, the
committee noted the challenge of providing coordinated
and integrated care, particularly among those patients
with a more severe form of dementia. Last, the subcommit-
tee examined the role of family members as the primary
care providers to individuals with dementia. Thus, it is
clear there are both regional and international efforts to
address the underlying causes of AD and dementia, its
diagnosis, treatment, and the development of services
and support mechanisms.
One of the critically important pieces of the National
Alzheimer’s Project was the call for the development of
service models, and to develop methods to deliver
high-quality, effective care based on the best available
evidence of efficacy. This is similar to what is already
being done in other countries, and mirrors the call that
was made by the Psychogeriatric Advisory Council to
the Health Service of Catalonia (Spain; Cognitive and
Behavioral Disorders in Social Health Care) in 1998 to
develop “concrete strategies and action[s] aimed at
improving the diagnosis, evaluation and monitoring of
the people affected” (p. 101 [5]). Indeed, many countries
in Europe now have national dementia strategies or are
committed to developing such strategies [6], and two of
these (Britain, France) were part of the analysis conducted
by the Senate Subcommittee on Aging.
There are a variety of model systems in place around the
world that provide a range of care services, each of which
model reflects the local cultural norms as well as government
and legal restrictions and expectations. A common thread in
all the discussions regarding research and services in AD and
related dementias is the need for coordination of activities.
Indeed, a coordinated site for providing clinical services in
a patient- and family-centered environment can provide
the backbone onto which coordinated clinical and basic
research can be placed. Fundacio ACE, Institut Catala de
Neurociences Aplicades (Fundacio ACE) has developed
one type of integrated care model in Barcelona (Spain)
that includes diagnosis, therapy, follow-up care, daycare,and a day hospital, and does so in the context of an active
clinical research program. The Alzheimer’s Education
Center (ACE) was established in 1991 and has evolved based
on the changing needs and demands of the patients and
their families, and based on changing evidence-based
therapies and management techniques. There are proposed
frameworks for comprehensive clinical and research settings
for AD and related dementias in the United States [7];
however, we describe the organization and inner workings
of Fundacio ACE, which has been in operation in Spain
for more than 15 years.
Fundacio ACE began the Memory Clinic in 1996 with the
goal of addressing the increasing demand for the treatment
and education for those individuals with dementia, and to
do so by offering personal attention to the patients and their
families. What began solely as a day center evolved to
include the Memory Clinic that now has a new 10-year
contract with the Health Ministry of the Government of
Catalonia, guaranteeing the services of the clinic through
2022. In addition to providing services through the health
system, Fundacio ACE also provides care on a fee-for-
service basis.2. The structure of Fundacio ACE
Fundacio ACE evolved an organizational structure that
allows it to meet the needs of patients, families, profes-
sionals, and researchers, and to respond to changes in these
needs over time. Details of the structure are presented in the
supplemental material, but, in brief, the center is divided into
five interacting groups that are managed by an administra-
tive team that is responsible for financial oversight, commu-
nication among the other seven teams, and communications
with external collaborators. The outreach team consists of
a full-time coordinator as well as independent contractors
who provide a comprehensive website and a monthly
electronic magazine, and who manage teaching activities
and international conferences. The Memory Disorders Unit
is similar to the clinical core of many of the AD research
centers in the United States. It is structured as a referral
center and receives patients from districts of greater
Barcelona, supported by the Health Ministry, as well as
private patients. The unit includes neurologists, geriatri-
cians, neuropsychologists, social workers, nurses, and
clinical and technical staff.
There is a continuity of care team that works with the
patients through the therapeutic day center. The center
serves as an alternative to hospitalization or institutionaliza-
tion; there is a daycare facility for people with late-onset
dementia, and a day hospital for people with early-onset
dementia. The daycare services group is designed to
enhance, preserve, and promote the independence of
patients in their basic activities of daily living and to
reduce caregiver burden. The team includes a medical
director, an assistant manager, a center coordinator, a hospi-
tal coordinator, neurologists, a geriatrician, psychiatrists,
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clinical assistants, occupational therapists, physical thera-
pists, and health care aides.
There is a team devoted specifically to research, which
includes brain imaging and clinical and basic research,
including genetics, bioinformatics, and clinical trials. The
neuroimaging group manages the first-line clinical neuroi-
maging modality (i.e., computerized axial tomographic
scanning) as well as research-level imaging procedures
that are parts of clinical trials and other funded research
(e.g., magnetic resonance imaging, single photon emission
computed tomography, positron emission tomography). A
clinical trials team carries out studies funded by the pharma-
ceutical industry. The bioinformatics group is comprised of
data management and biostatistics teams, including data
managers and doctoral-level biostatisticians and physicists,
a doctoral-level psychologist as well as information technol-
ogy consultants who build and maintain the computer
infrastructure for Fundacio ACE, and who work to design
experiments and analyze data from the researchers. Last,
there is a basic research group that focuses on genetics.
Fundacio ACE has a laboratory that facilities that processing
of samples from all newly enrolled patients so the foundation
can participate in genomewide association studies as well as
biomarker studies.
All patients undergo standardized neurobehavioral ex-
aminations, including neuropsychological [8] and social
work evaluations, as well as appropriate laboratory and
neuroimaging studies. All diagnoses are assigned by
the clinical team at a daily consensus conference. The
diagnosis of AD is based on the National Institute of
Neurological and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association
criteria [9]; standard research-level diagnostic criteria are
used for the classification of vascular dementia [10,11],
frontotemporal dementia [12,13], Lewy body dementia
[14], Parkinson’s disease [15], and other relevant
conditions affecting cognition in the elderly (e.g., depres-
sion using Diagnostic and Statistical Manual of Mental
Disorders, fourth edition [16]).
Mild cognitive impairment (MCI) is classified in terms of
amnestic and nonamnestic MCI by using the current criteria
[17,18], and requires the presence of measurable alterations
in cognitive functions not sufficient to warrant diagnosis of
dementia. Patients (or their caregivers) must report
alterations in memory and/or cognition, but there can be
no decline in general intellectual abilities.
However, the diagnostic criteria for MCI within the
center changed during the past 15 years. Prior to 2006,
patients who would have later met the criteria for MCI
were classified as having age-related cognitive impairment,
age-related memory impairment, or MCI (using the 1999
criteria [17]). From 2006 onward, the center used the current
research criteria [18,19] and added the additional qualifiers
of probable (i.e., uncomplicated by concomitant medical
conditions) and possible (i.e., with an associated medicalcondition that could account for the impairment) [20].
Patients were further differentiated by the presence or
absence of a memory deficit.
Patients are referred to the Memory Clinic by their
primary care physician, a consulting neurologist, or a psy-
chiatrist, for example. There is an initial interview by the
social worker with the family (40 minutes) followed by
an interview of the family by the neurologist (30 minutes)
and a neurological examination of the patient (30 minutes).
A neuropsychological evaluation (50 minutes) follows, and
the results are collated for presentation at the next day’s
consensus conference (w10–15 minutes per patient)
(see Supplemental Table E-1). The final diagnosis using
established research-level criteria (mentioned earlier) is
based on the results of the neurological, neuropsychologi-
cal, and social work valuations. A therapeutic plan is
developed that can include pharmacological and nonphar-
macological therapies, as well as access to social
resources. A second appointment is scheduled, at which
time the family and patient are informed of the diagnosis
and therapeutic options are discussed (30 minutes).
For follow-up visits, a similar sequence is used, but the
neurological examination is more focused (30 minutes)
and the families spend the time with the social worker
(30 minutes); the neuropsychological evaluation is repeated
in its entirety (50 minutes). For those patients who are
supported by the Catalan Health Service, funds are provided
to support the three components of the visit. Of those pa-
tients whose dementia has progressed to a moderate-severe
stage (i.e., a Clinical Dementia Rating 2 points), the
neuropsychological evaluation is replaced by a more
extensive social work interview (i.e., w80 minutes) to
provide additional support to the patient and family. For
private-pay patients (including those with private insurance
policies), a similar plan is used (i.e., private pay does not
result in additional attention or services).3. The growth of Fundacio ACE
A total of 13,048 patients enrolled in Fundacio ACE
from 1996 through December 2011. The annual rate of
examinations increased to 1773 in 2011 from 390 in 1996;
the cumulative number of all patients enrolled in the center
is shown in Figure 1. Figure 2 shows the cumulative totals of
the patients with AD and MCI.
Table 1 shows the basic characteristics of the patients
broken down into summary diagnostic groups. A group
of cognitively normal elderly subjects was recruited into
a research project [21], and provides important compara-
tive information. There are significant differences in
age (F[6, 11,741] 5 405.3, x2 5 0.17), Global Deteri-
oration Scale score (F[6, 6932] 5 1661.5, x2 5 0.59),
and Mini-Mental State Examination score (F[6,
6829] 5 713.2, x2 5 0.39) such that the AD patients are
older than the control subjects and the MCI patients,
and have lower summary measures of mental status at
Fig. 1. Cumulative enrollment of all patients in Fundacio ACE from 1996
through 2011.
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Women were more common than men in all groups (P
, .05). The patients without cognitive impairment were
younger than those with cognitive disorders (least signif-
icant difference test, P , .05). The characteristics of the
MCI patients who entered after 2005 are shown in
Table 2.
The number of follow-up visits increased to 3579 in
2011 (a total of 5532 evaluations) from 256 in 1997 (65%
of new patients). The median number of years of follow-
up for all patients through 2011, from entry until their
last visit, is 2.85 years (95% confidence interval, 2.78–
2.92). Because the rate of enrollment is increasing, the me-
dian follow-up does not reflect the whole picture. For the
patients enrolled in 2001, who had 10 years of possible
follow-up, the mean time as a clinic patient is 6.98 6
2.65 years. For those who enrolled in 2006, who have
only 5 years of possible follow-up, the mean time as a clinic
patient is 3.68 6 1.89 years.
At least one follow-up visit was available for the 1396 pa-
tients who were initially classified with MCI after 2005.
Seventy-three percent of the probable MCI patients devel-
oped AD during follow-up, and 51% of the possible MCI pa-
tients developed dementia. Nonamnestic MCI evolved into
clinical dementia in 33% of the patients.Fig. 2. Cumulative enrollment of patients as a function of diagnostic
groups. AD, Alzheimer’s disease; MCI, mild cognitive impairment.4. Discussion
Fundacio ACE has provided diagnosis, management,
daycare, and day hospital facilities for the citizens in the
catchment area around the city center of Barcelona since
1996. The primary diagnosis identified among the more
than 13,000 patients was probable AD, accounting for
47% of the patients with cognitive disorders. MCI accounted
for a further 30% of individuals, and approximately 15% of
all patients referred for evaluation were classified as having
subjective complaints of cognitive impairment with no ob-
jective findings.Fundacio ACE can serve as a model system to be adapted
to other settings within local cultural, government, and legal
constraints. Any new service models developed as a conse-
quence of the National Alzheimer’s Project, for example,
must be flexible enough to adapt to both short-term and
long-term changes in the needs of the patients and families.
One of the important differences between the plans outlined
in the 1998 Catalan and the 2012 U.S. the National Alz-
heimer’s Project was the relative emphasis on families and
on institutional care. Reliance on informal family caregivers
likely reflects not only the (un)availability of a formal ser-
vices, but also cultural norms [3]. Thus, although the United
States places greater emphasis on group or institutional care
(while paradoxically not providing adequate funding), coun-
tries such as Spain rely more heavily on families to care for
the ill and infirm. This is reflected in the organization and op-
eration of Fundacio ACE. In addition to day hospital services
for individuals with memory complaints or mild dementia
(which also serves as respite care for caregivers), Fundacio
ACE also offers educational services and specialized infor-
mation to the families of the patients free of charge. The
foundation’s professional educational efforts focus on the
geriatricians, neurologists, and psychiatrists who are the ini-
tial point of contact for the patients and families, and who
make the initial referrals to the Memory Clinic, and who
are responsible for many aspects of the general health care
of the patients.
The integration of the diagnosis and management of pa-
tients with cognitive disorders is facilitated by the organiza-
tion of the health care system in Spain. To be enrolled in
a dementia clinic such as that at Fundacio ACE, the patients
must be referred by their primary care provider or a consul-
ting physician, who is responsible for parts of the initial eval-
uation, including laboratory studies and brain imaging.
However, the neurological examination, psychiatric evalua-
tion, social work assessment, and neuropsychological evalu-
ation are all completed as part of the work of the Memory
Clinic. The information from these specialty examinations
Table 2
Characteristics of Fundacio ACE MCI participants after 2005
Characteristic
Probable
amnestic MCI
Possible
amnestic MCI
Non-amnestic
MCI Statistics*
n 167 523 291 981
Age, years 77.4 (6.3) 75.5 (8.0) 75.4 (8.3) 4.89 (.02)
Educationy 46.4 (70) 40.7 (188) 52.1 (137) 8.91 (.10)
Sexz 62.9 (105) 70.2 (367) 64.6 (188) 4.41 (.07)
APOE ε4x 52.3 (46) 36.7 (61) 18.5 (10) 16.4 (.23)
GDS score,
points
2.98 (.21) 2.96 (.26) 3.00 (.00) 0.46 (.00)
MMSE score,
points
24.7 (2.9) 25.0 (3.5) 26.3 (2.7) 17.1 (.48)
Abbreviations: ACE, Alzheimer’s Education Center;MCI, mild cognitive
impairment; APOE, apolipoprotein E; GDS, Global Deterioration Scale;
MMSE, Mini-Mental State Examination.
NOTE.Values for Age, GDS, andMMSE are presented asmean (standard
deviation).
*c2 or F (Phi or h2).
yPercent (n) with at least elementary school education. Total with educa-
tion levels is 876.
zPercent (n) female.
xPercent (n) with at least one copy of the ε4 allele. Total with APOE geno-
typing is 308.
Table 1
Characteristics of Fundacio ACE participants
Characteristic Probable AD Possible AD Other dementias
Mild cognitive
impairment Other conditions
Subjective
complaints
Healthy
elderly
n 4530 517 1314 2028 1929 1218 73
Age, years 85.1 (7.8) 83.6 (7.7) 82.3 (9.0) 79.8 (8.9) 78.6 (11.9) 71.5 (12.1) 71.5 (8.4)
Education* 26.8 (973) 37.8 (272) 40.0 (536) 43.8 (945) 39.8 (700) 57.9 (342) 67.1 (49)
Sexy 74.3 (3367) 74.1 (383) 60.7 (797) 66.3 (1345) 60.7 (1170) 65.0 (792) 60.3 (44)
APOE ε4z 46.0 (645) 43.4 (86) 28.3 (75) 37.8 (253) 31.6 (74) 21.2 (18) 20.0 (12)
GDS score, points 4.54 (.82) 4.60 (.80) 4.38 (.88) 2.97 (.22) 3.53 (1.1) 2.00 (.25) 1.27 (.48)
MMSE score, points 17.4 (5.6) 18.3 (5.3) 20.4 (5.6) 25.3 (3.4) 23.0 (5.9) 28.6 (1.44) 29.6 (.79)
Abbreviations: ACE, Alzheimer’s Education Center; AD, Alzheimer’s disease; APOE, apolipoprotein E; GDS, Global Deterioration Scale; MMSE, Mini-
Mental State Examination.
NOTE. Values for Age, GDS, and MMSE are presented as mean (standard deviation).
*Percent (N) with at least elementary school education. Total with education levels is 10,419.
yPercent (n) female.
zPercent (n) with at least one copy of the ε4 allele. Total number genotyped is 2913.
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passed back to the primary physician, who is responsible
for the total care of the patient’s health. However, therapy
(especially pharmacotherapy) is the responsibility of
Fundacio ACE.
From a research perspective, the patients enrolled and
followed in Fundacio ACE provide a unique window into
the characteristics of patients with dementia syndromes
because they are typically seen in clinical care. Unlike re-
search centers that focus on the identification of participants
with few if any medical complications (because they are
needed for pharmaceutical trials), Fundacio ACE enrolls
all-comers. As such, the research team is in a position to
confirm and extend findings from tertiary care research
centers in a more clinically diverse population. Furthermore,
as the number of Fundacio ACE patients who are genotyped
increases, it will be possible to examine the relative impact
of various newly identified single nucleotide polymorphisms
and their role in modifying risk for sporadic AD [22–31].
Indeed, the patients from Fundacio ACE serve as an
excellent confirmation sample because they have not
provided their genetic material to other studies, and thus
the data are entirely independent of other genomewide
association studies.
Fundacio ACE provides a good, working model for inte-
grated care in dementia. From the initial point of contact,
patients and their families have a range of services that are
offered to them by the Health Service through Fundacio
ACE, including pharmacological and nonpharmacological
therapeutic interventions, daycare, and a day hospital
[32,33]. The availability of patient-centered day services,
especially those that provide respite for families and stimu-
lation for patients, could potentially extend the period of
higher quality of life, thus meeting one of the primary goals
of the care of patients with AD and related dementias.
One of the principal differences between the care
model implemented in Fundacio ACE and those used
more commonly in the United States and other countries
is the lack of a comprehensive approach to the care ofthe patients and their families in these other settings.
As noted by the Senate Subcommittee on Aging [3],
care of demented patients tends to be fragmented,
whereas in Fundacio ACE, care and management is
more fully integrated. We are not aware of other clinics
with this kind of integrated system that are generally
open and available to all people in need, regardless of
their ability to pay.
The World Health Organization has recommended that
priority should be given to dementia research as a public
health agenda [34], a call that is reminiscent of a proposal
made in 2006: “Epidemiological surveillance is an essential
instrument for planning, managing and distributing commu-
nity health resources, for following up the natural history of
chronic diseases and for assessing the impact of programmes
of prevention” [35]. Fundacio ACE is able to integrate
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supporting intervention trials, but also by the use of the
patient database to provide insight into the natural and
treated history of AD and related dementias. Lopez-Pousa
and colleagues [35] outlined a simple, minimal (i.e.,
36-item) data set that could significantly advance our under-
standing of AD and related dementias, and this was shown to
be a viable method for obtaining information about the
prevalence and characteristics of dementia [36]. This kind
of data could then be used to study intra- and interregional
trends, and might be of particular use in resource-limited
areas. An effort such as this would require the cooperation
of scores of facilities and would require sufficient funding
to support an independent data management and analysis
system. However, there could be “a sequential implementa-
tion of the registry. so that it can be adapted to each health
district or region” [35]. Thus, as we have emphasized
regarding the development of the Fundacio ACE clinical
services, such a registry must be allowed to evolve, with
the specific national, regional, and local variations to allow
for the acquisition of relevant data.
The goal of this article was to describe the workings of an
existing AD care center that seems to meet many of the
requirements specified by the National Alzheimer’s Project
and by other international efforts to address AD and related
dementias. What we cannot report is a cost–benefit analysis
or an econometric modeling of the services provided by
Fundacio ACE. Not only is this beyond our expertise and
our available data, but the results likely would not generalize
to other regions or countries with different health and social
services, and different cultural expectations. However, we
believe that Fundacio ACE is able to deliver the services
that are suggested by the various national plans, and it
does so in a cost-efficient manner.
The U.S. National Alzheimer’s Project acknowledges:
“Many nations have developed Alzheimer’s plans of their
own that involve improved care and supports for people
with Alzheimer’s disease and their caregivers, as well as
enhanced research and public awareness. In implementing
the actions in this plan, [Health and Human Services] and
its federal partners will coordinate with global partners to
enhance these plans, avoid duplication of effort, and
optimize existing resources” (p. 30 [4]). The experience of
Fundacio ACE has much to contribute to these efforts. The
specific methods and organization of Fundacio ACE are
likely not generalizable to all parts the world; but, the
success of Fundacio ACE shows that a model of integrated,
patient-centered care with a built-in research emphasis, can
be used elsewhere. Each center must evolve based on
regional constraints and on the needs of the patients, their
families, and the professionals who care for them.Acknowledgments
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1. Systematic Review: The U.S. government passed the
National Alzheimer’sProject Act, which requires the
U.S. Department of Health and Human Services to
establish the National Alzheimer’s Project to create
and maintain an integrated national plan to overcome
Alzheimer’s disease (AD). One of the critically im-
portant pieces of this project is the call for the devel-
opment of service models, and to develop methods
that are used to deliver high-quality, effective care
based on the best available evidence of efficacy.
2. Interpretation: This report describes the workings of
an existing AD care center in Spain that seems to
meet many of the requirements specified by the Na-
tional Alzheimer’s Project and by other international
efforts to address AD and related dementias.
3. Future Directions: The specific methods and organi-
zation of the center are likely not generalizable to all
parts the world; however, the success of the center
shows that a model of integrated, patient-centered
care, with a built-in research emphasis, can be used.References
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